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Murine modelHyperhomocysteinemia due to cystathionine beta synthase deﬁciency confers diverse clinical manifestations. It
is characterized by elevated plasmahomocysteine levels, a common amino acidmetabolized by remethylation to
methionine or transsulfuration to cysteine.We recently found a relationship between hepatic Dyrk1Aprotein ex-
pression, a serine/threonine kinase involved in signal transduction in biological processes, hepatic S-
adenosylhomocysteine activity, and plasma homocysteine levels. We aimed to study whether there is also a re-
lationship between Dyrk1a and cystathionine beta synthase activity. We used different murine models carrying
altered gene coy numbers for Dyrk1a, and found a decreased cystathionine beta synthase activity in the liver of
mice under-expressing Dyrk1a, and an increased in liver of mice over-expressing Dyrk1a. For eachmodel, a pos-
itive correlation was found between cystathionine beta synthase activity and Dyrk1a protein expression in the
liver of mice, which was conﬁrmed in a non-modiﬁed genetic context. The positive correlation found between
liver Dyrk1a protein expression and CBS activity in modiﬁed and non-modiﬁed genetic context strengthens
the role of this kinase in one carbon metabolism.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Homocysteine (hcy) is an intermediate in the sulfur amino acid me-
tabolism. Once hcy is formed, it may be metabolized by remethylation
to methionine or transsulfuration to cysteine. Cystathionine beta syn-
thase (CBS), which gene is localized on human chromosome 21, is the
ﬁrst enzyme involved in the transsulfuration pathway and catalyzes
the condensation of hcy with serine to form cystathionine. Hcy can
also turn back to S-adenosylhomocysteine (SAH) via reversal of the
SAH hydrolase (SAHH) reaction [1]. Homocystinuria or severe hyperho-
mocysteinemia, deﬁned by elevated plasma hcy level, is ametabolic dis-
order with defect in genes encoding for methionine metabolism
enzymes. The clinical features consist in ophthalmic, neurologic, ortho-
pedic and vascularmanifestations. Homocystinuria ismainly due to CBS, Down syndrome; DYRK, dual-
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. This is an open access article underdeﬁciency. It is the second metabolic encephalopathy in order of fre-
quency [2]. The disorder is also associated with cognitive dysfunctions
such as intellectual disability, cerebral atrophy, and seizures [2,3]. Fur-
ther, elevated hcy level has also been associated with neurological dis-
orders such as epilepsy [4,5].
The identiﬁcation of intragenic DYRK1A rearrangements or 21q22
micro-deletions including only DYRK1A in patients with intellectual
disability, microcephaly, seizures and epilepsy hypothesized the role
of DYRK1A for such a phenotype [6–11]. Dyrk1A,which gene is localized
on human chromosome 21, is a protein kinase that belongs to an evolu-
tionarily conserved family of proteins known as DYRK (dual-speciﬁcity
tyrosine-(Y)-phosphorylation regulated kinase) thatmight be responsi-
ble for intellectual disability in Down's syndrome (DS) patients [12].We
recently analyzed the expression of Dyrk1A in the liver of CBS-deﬁcient
mice, a murine model of hyperhomocysteinemia, and found a
reduced protein level, concomitant with a decreased hepatic SAHH
activity [13–15]. On the contrary, an over-expression of Dyrk1A de-
creased plasma hcy level and increased the hepatic SAHH activity by a
mechanism dependent of NAD(P)H:quinone oxidoreductase (NQO1)
activity [15]. We therefore have established a link between hepatic
Dyrk1a expression, hepatic SAHH activity and plasma hcy levels. How-
ever, the key question asked now is to study whether there is also a re-
lationship between Dyrk1a and CBS. To analyze further the relation
between Dyrk1a and CBS, we used two mice models to demonstratethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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hepatic CBS activity. We also used a spontaneous nonobese model of
type 2 diabetes with lower plasma hcy level and increased liver CBS ac-
tivity [16] to conﬁrm the link established in modiﬁed genetic context.
2. Materials and methods
2.1. Animals
All Animal care was conducted in accordance with internal guide-
lines of the French AgricultureMinistry for animal handling (authoriza-
tion number 75–369). Mice and rats were housed in a controlled
environment (temperature= 20± 1 °C; humidity = 60%) with unlim-
ited access to food andwater on 12-h light/dark cycle. A number ofmice
and rats and suffering were minimized as possible. Mice carrying the
mBACtgDYRK1A construct were maintained on a C57BL/6 J background
and genotyped as described [17]. Dyrk1a (+/−) mice were maintained
on a CD1 background and genotyped as described [18]. The Goto-
Kakizaki (GK) line was established by repeated inbreeding fromWistar
rats selected at the upper limit of normal distribution for glucose toler-
ance [19,20]. All experiments were conducted on age-matched control
animals.
2.2. Sample preparation, tissue collection, and plasma total hcy assay
Following euthanization of mice and rats, blood samples were ob-
tained by retro-orbital sinus sampling with heparinized capillaries, col-
lected into tubes containing a 1/10 volume of 3.8% sodium citrate, and
immediately placed on ice. Plasma was isolated by centrifugation at
2500 ×g for 15 min at 4 °C. The liver was rapidly removed and snap-
frozen in liquid nitrogen before being stored at−80 °C until use. Plasma
total hcy, deﬁned as the total concentration of hcy after quantitative re-
ductive cleavage of all disulﬁde bonds, was assayed using the ﬂuorimet-
ric high-performance liquid chromatography (HPLC) method described
by Fortin and Genest [21]. The inter- and intra-assay coefﬁcients of var-
iation for mean total hcy level were 4.2% and 6.3% respectively and the
linearity was from 1 to 100 μM [22].
2.3. Dyrk1a protein analysis by slot blot
Protein samples were prepared by homogenizing the liver in 500 μL
phosphate-buffered saline with a cocktail of proteases inhibitors. Pro-
tein concentrations were detected with the Bio-Rad Protein Assay re-
agent (Bio-Rad). To assess the relative amount of Dyrk1a, we used a
slot blot method previously developed [23]. Protein preparations were
blotted on Hybond-C Extra membrane (GE Healthcare Europe GmbH)
using Bio-Dot SF Microﬁltration Apparatus (Bio-Rad). After transfer,
membraneswere saturated by incubation in 5%w/v nonfatmilk powder
in Tris-saline buffer (1.5 mM Tris base, pH 8; 5 mM NaCl; 0.1% Tween-
20), and incubated overnight at 4 °C with an antibody directed against
DYRK1A (1/500) (Abnova corporation, Tebu, France). Binding of the pri-
mary antibodywas detected by incubationwith horseradish peroxidase
(HRP)-conjugated secondary antibody using the Western Blotting
Luminol Reagent (Santa Cruz Biotechnology, Tebu, France). Ponceau-S
coloration (Sigma-Aldrich, France) was used as an internal control. Dig-
itized images of the immunoblots obtained using an LAS-3000 imaging
system (Fuji Photo Film Co., Ltd.) were used for densitometric measure-
ments with an image analyzer (UnScan It software, Silk Scientiﬁc Inc.).
2.4. CBS enzyme activity assays
Determination of CBS activitywas assayed on 400 μg of total proteins
obtained from liver samples, as described [24]. Proteins were incubated
for 1 h at 37 °C with 1 mM of propargylglycine, 0.2 mM of pyridoxal
phosphate (PLP), 10 mM of L-serine, 10 mM of DL-Hcy, 0.8 mM of
SAM, using DTNB (5,5′-dithiobis-(2-nitrobenzoic acid)) based-assay.All the chemical products were obtained from Sigma (Sigma-Aldrich,
France).
2.5. Data analysis
Statistical analysis was performedwith one-way analysis of variance
(ANOVA) followed by Fisher's post-hoc test using Statview software.
The results are expressed as medians with interquartile ranges. Data
were considered signiﬁcant when p ≤ 0.05. Correlations between
Dyrk1a protein level and CBS activity were determined by using
Spearman's rank correlation, as data were not normally distributed ac-
cording to Shapiro–Wilk test.
3. Results
3.1. CBS activity is decreased in liver of mice under-expressing Dyrk1a
We ﬁrst conducted the analysis of CBS activity in the liver of mice
carrying only one copy of Dyrk1A, the Dyrk1a (+/−) mice [18]. The de-
creased protein expression of Dyrk1a (Fig. 1A), analyzed by slot blot
method previously validated [23], was associated with a decreased
CBS activity in liver of Dyrk1a (+/−) mice compared to control (wild
type) mice (Fig. 1B). We observed a signiﬁcant positive correlation be-
tween the liver CBS activity and liver Dyrk1A protein expression (ρ=
0.867, p b 0.009). Commensurate with the decreased hepatic CBS activ-
ity, plasma hcy levels were increased in Dyrk1a (+/−) mice compared
to control (wild type) mice (Fig. 1C).
3.2. CBS activity is increased in liver of mice over-expressing Dyrk1a
We also conducted the analysis of CBS activity in the liver of mice
carrying the murine BAC containing one copy of the entire murine
Dyrk1a gene, the mBACtgDyrk1a mice [17]. The increased protein ex-
pression of Dyrk1a (Fig. 2A)was associatedwith an increased CBS activ-
ity in the liver of mBACtgDyrk1a mice compared to control (wild type)
mice (Fig. 2B). We also observed a signiﬁcant positive correlation be-
tween the liver Dyrk1A protein expression and CBS activity (ρ =
0.603, p b 0.006). As previously described [15], plasma hcy levels were
decreased in mBACtgDyrk1a mice compared to control (wild type)
mice (Fig. 2C).
3.3. Dyrk1a protein expression is increased in liver of GK rats with increased
CBS activity
Wepreviously found a lower plasma level of hcy concomitantlywith
an increased liver activity of CBS in GK rats, a spontaneous nonobese
model of type 2 diabetes [16]. We therefore used this rat model in
order to analyze the hepatic Dyrk1a protein expression in a non-
modiﬁed genetic context. The increased protein expression of Dyrk1a
(Fig. 3A) was associated with an increased CBS activity in the liver of
GK rats compared to nondiabetic Wistar (wild type) rats (Fig. 3B). We
also observed a signiﬁcant positive correlation between liver Dyrk1A
protein expression and CBS activity (ρ=0.625, p b 0.02). As previously
described [15], plasma hcy levels were decreased in GK rats compared
to Wistar (wild type) rats (Fig. 3C).
4. Discussion
Dyrk1a encodes a dual-speciﬁcity tyrosine-phosphorylation-
regulated kinase, which has been shown to play an important role in
signaling transduction in biological processes. Along with quantifying
the link between CBS activity andDyrk1a, we used two differentmodels
carrying altered gene copy numbers for Dyrk1a: a mBACtgDyrk1a
model with three copies of the murine Dyrk1a gene and a Dyrk1a
(+/−)modelwith only one copy. For eachmodel, a positive correlation
was found between the liver CBS activity and liver Dyrk1a protein
Fig. 1.Hepatic dyrk1A protein expression, CBS activity, and plasma hcy levels inmice under-expressing Dyrk1a. (A) Dyrk1A protein expressionwas analyzed by slot blotting in the liver of
wild type (WT) and mice under-expressing Dyrk1a (Dyrk1a (+/−)). (B) CBS activity in the liver of wild type (WT) and mice over-expressing Dyrk1a (Dyrk1a (+/−)). Data were nor-
malized to the mean of wild-type (WT) mice. (C) Plasma hcy level. Data correspond to the medians with interquartile ranges. n = number of mice.
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context, a spontaneous nonobese rat model of type 2 diabetes. We pre-
viously reported a reduction of Dyrk1a protein level in the liver of CBS-
deﬁcient mice [14], suggesting a link between Dyrk1a related pathways
and the hcy cycle. We also previously showed that the over-expression
of Dyrk1a diminishes the plasma hcy level [15], which is conﬁrmed in
this present study with the murine mBACtgDyrk1a model. This result
was obtained with different murine models which contain the human
(a YAC transgenic for a human chromosome 21 fragment carrying ﬁve
genes including PIGP, TTC3, DSCR9, DSCR3 and Dyrk1a) or the murine
gene (the mBACtgDyrk1a model) and correlates with an increased he-
patic SAHH activity [15]. However, unlike the present study, we found
no effect on hepatic CBS activity in YAC transgenic mice in agreement
with the hepatic SAM levels (an allosteric activator of CBS) [15]. Even
if the difference does not share statistical differences, hepatic levels of
SAM and SAM/SAH ratio were increased in mBACtgDyrk1a mice. CBS
catalyzes the PLP-dependent condensation of serine with hcy. We re-
cently found that an adenoviral construct designed to restrict expres-
sion of Dyrk1a to hepatocytes decreased plasma hcy levels in CBS
deﬁcientmice [25]. This resultwas associatedwith a signiﬁcant increase
in hepatic PLP, hepatic SAM/SAH ratio, hepatic CBS activity and SAHH
activity [25]. Taken together, our results reinforce the role of Dyrk1a in
one carbon metabolism.Minimal deletions in the region where human DYRK1A maps have
been described in partial monosomy 21 patients [26], who present mi-
crocephaly, intellectual disability, intrauterine and postnatal growth re-
tardation, characteristic physical features, seizures, epilepsy andmild to
severe MRI alterations resembling brain atrophy, and idiopathic throm-
bocytopenia [8]. Dyrk1a (+/−) mice present reductions in brain size,
possible intrauterine growth retardation, and postnatal growth retarda-
tion. The striking phenotypic similarities between Dyrk1a (+/−) mice
and partial monosomy 21 patients suggest that some of the characteris-
tic features of partialmonosomy 21 could be directly related to the dose
reduction of Dyrk1a [18]. Truncation mutations of DYRK1A result in a
severe clinical phenotype including microcephaly [6]. A microdeletion
in DYRK1A induces similar phenotypes [9]. On clinical reexamination
at 13 years of age, one patient had pectus excavatum, kyphosis, and
slight scoliosis, and his skin was very thin [6]. Some phenotypes seen
in these patients were compatible with the phenotype of CBS deﬁcient
patients. The major clinical manifestations of CBS deﬁcient patients in-
clude intellectual disability, developmental retardation, seizures, behav-
ioral or psychiatric disorder, dislocation of the optic lens, skeletal
abnormalities, and early thromboembolic disorder and decreased plate-
let survival time [2,27]. Up to 20% of CBS deﬁcient patients have seizures
[28]. Elevated CSF hcy levels have been shown to compromise blood–
brain barrier integrity and reduce seizure threshold in rodents
Fig. 2. Hepatic dyrk1A protein expression, CBS activity, and plasma hcy levels in mice over-expressing Dyrk1a. (A) Dyrk1A protein expression was analyzed by slot blotting in the liver of
wild type (WT) andmice over-expressing Dyrk1a (mBACtgDyrk1a). (B) CBS activity in the liver of wild type (WT) andmice over-expressing Dyrk1a (mBACtgDyrk1a). Data were normal-
ized to the mean of wild-type (WT) mice. (C) Plasma hcy level. Data correspond to the medians with interquartile ranges. n = number of mice.
Fig. 3.Hepatic dyrk1A protein expression, CBS activity, and plasma hcy levels inGK andWistar rats. (A) Dyrk1A protein expressionwas analyzed by slot blotting in the liver ofWistar (WT)
and Goto-Kakizaki (GK) rats. (B) CBS activity in the liver of Wistar (WT) and Goto-Kakizaki (GK) rats. Data were normalized to the mean of Wistar (WT) rats. (C) Plasma hcy level. Data
correspond to the medians with interquartile ranges. n = number of rats.
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amino-butyric-acid (GABA) receptor, an inhibitory neurotransmitter
in the neuronal synapse. Epileptogenesis induced by pentylenetetrazole
(PTZ) caused a signiﬁcant increase in serum hcy in comparison to con-
trol rats [32]. Unlüçerçi and colleagues [33] also reported increase of
serum hcy levels in epilepsy. Elevated hcy levels were found to inhibit
GABA by competing with it for attachment to its receptors [34]. Indeed,
mBACtgDyrk1a mice with increased dosage of Dyrk1a and decreased
plasma hcy levels are protected against PTZ-induced seizures [34]. Con-
versely, Dyrk1a (+/−) mice with increased plasma hcy levels, display
more convulsions following PTZ administration [35]. Increased Dyrk1a
expression and low plasma hcy levels have been associated with DS,
the most common genetic cause of signiﬁcant cognitive disability [36,
37]. However until now, plasma hcy levels were not analyzed in partial
monosomy 21 patients.
By identifying metabolic alterations associated with cognitive im-
pairment, it may be possible to developmedical or dietary interventions
to ameliorate cognitive disabilities in persons with DS. Thus, among the
genes from the common duplicated region and deleted regions, Dyrk1a
is the best candidate gene for cognitive impairment phenotypes. There
is evidence that CBS enzyme activity is increased in persons with DS
[38]. If CBS, which gene is on chromosome 21, also contributes to the
cognitive disability seen in persons with DS, then treatments that de-
crease the enzyme activity would also be desirable. De la Torre and col-
leagues recently demonstrated that green tea ﬂavonol epigallocatechin-
gallate (EGCG), an inhibitor of Dyrk1a, reverses the cognitive deﬁcits in
a pilot study in DS individuals with effects on memory recognition,
working memory and quality of life [39]. In light of the present results,
if EGCGwill be a promising therapeutic tool for cognitive enhancement
in DS, it would be interesting to analyze its effect targeting abnormali-
ties of one carbon metabolism.
5. Conclusions
A positive correlation was found between the liver Dyrk1a protein
expression and CBS activity in modiﬁed and non-modiﬁed genetic con-
text, which reinforces the role of this kinase in one carbon metabolism.
Acknowledgments
This work was supported by the Fondation Jérôme Lejeune
(30CA1140087) and the Association Gaspard Félix (L'AGAFE)
(30S1B07). We acknowledge the platform accommodation and an-
imal testing of the animal house at the Institute Jacques-Monod
(University Paris Diderot).
References
[1] J. Selhub, Homocysteine metabolism, Annu. Rev. Nutr. 19 (1999) 217–246.
[2] S.H. Mudd, F. Skovby, H.L. Levy, K.D. Pettigrew, B. Wilcken, R.E. Pyeritz, The natural
history of homocystinuria due to cystathionine beta-synthase deﬁciency, Am. J.
Hum. Genet. 37 (1985) 1–31.
[3] P.S. Sachdev, M. Valenzuela, X.L. Wang, J.C. Looi, H. Brodaty, Relationship between
plasma homocysteine levels and brain atrophy in healthy elderly individuals, Neu-
rology 58 (2002) 1539–1541.
[4] P.S. Sachdev, Homocysteine and brain atrophy, Prog. Neuropsychopharmacol. Biol.
Psychiatry (2005) 1152–1161.
[5] R. Obeid, A. McCaddon, W. Herrmann, The role of hyperhomocysteinemia and B-
vitamin deﬁciency in neurological and psychiatric diseases, Clin. Chem. Lab. Med.
45 (2007) 1590–1606.
[6] R.S. Moller, S. Kubart, M. Hoeltzenbein, B. Heye, I. Vogel, C.P. Hansen, C. Menzel, R.
Ullmann, N. Tommerup, H.H. Ropers, Z. Tumer, V.M. Kalscheuer, Truncation of the
Down syndrome candidate gene DYRK1A in two unrelated patients with micro-
cephaly, Am. J. Hum. Genet. (2008) 1165–1170.
[7] T. Yamamoto, K. Shimolima, T. Nishizawa, M. Matsuo, M. Ito, K.T. Imai, Clinical man-
ifestations of the deletion of Down syndrome critical region including DYRK1A and
KCNJ6, Am. J. Med. Genet. A 155 (2011) 113–119.
[8] R. Oegema, A. de Klein, A.J. Verkerk, R. Schot, B. Dumee, H. Douben, B. Eussen, L.
Dubbel, P.J. Poddighe, I. van der Laar, W.B. Dobyns, P.J. van der Spek, M.H. Lequin,
I.F. de Coo, M.C. de Wit, M.W. Wessels, G.M. Mancini, Distinctive phenotypicabnormalities associated with submicroscopic 21q22 deletion including DYRK1A,
Mol. Syndromol. 1 (2010) 113–120.
[9] B.W. van Bon, A. Hoischen, J. Hehir-Kwa, A.P. de Brouwer, C. Ruivenkamp, A.C.
Gijsbers, C.L. Marcelis, N. de Leeuw, J.A. Veltman, H.G. Brunner, B.B. de Vries, Intra-
genic deletion in DYRK1A leads to mental retardation and primary microcephaly,
Clin. Genet. 79 (2011) 296–299.
[10] J.B. Courcet, L. Faivre, P. Malzac, A. Masurel-Paulet, E. Lopez, P. Callier, L. Lambert, M.
Lemesle, J. Thevenon, N. Gigot, L. Duplomb, C. Ragon, N. Marle, A.L. Mosca-Boidron,
F. Huet, C. Philippe, A. Moncla, C. Thauvin-Robinet, The DYRK1A gene is a cause of
syndromic intellectual disability with severe microcephaly and epilepsy, J. Med.
Genet. 49 (2012) 731–736.
[11] A. Valetto, A. Orsini, V. Bertini, B. Toschi, A. Bonuccelli, F. Simi, I. Sammartino, G.
Taddeucci, P. Simi, G. Saggese, Molecular cytogenetic characterization of an intersti-
tial deletion of chromosome 21 (21q22.13q22.3) in a patient with dysmorphic fea-
tures, intellectual disability and severe generalized epilepsy, Eur. J. Med. Genet. 55
(2012) 362–366.
[12] Y.S. Ryu, S.Y. Park, M.S. Jung, S.H. Yoon, M.Y. Kwen, S.Y. Lee, S.H. Choi, C.
Radnaabazar, M.K. Kim, H. Kim, K. Kim, W.J. Song, S.H. Chung, Dyrk1A-mediated
phosphorylation of Presilin 1: a functional link between Down syndrome and
Alzheimer's disease, J. Neurochem. 115 (2010) 574–584.
[13] M. Watanabe, J. Osada, Y. Aratani, K. Kluckman, R. Reddick, M.R. Malinow, N. Maeda,
Mice deﬁcient in cystathionine beta-synthase: animal models for mild and severe
homocyst(e)inemia, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1585–1589.
[14] J. Hamelet, C. Noll, C. Ripoll, J.L. Paul, N. Janel, J.M. Delabar, Effect of hyperhomocys-
teinemia on the protein DYRK1A in liver of mice, Biochem. Biophys. Res. Commun.
378 (2009) 673–677.
[15] C. Noll, C. Planque, C. Ripoll, F. Guedj, A. Diez, V. Ducros, N. Belin, A. Duchon, J.L. Paul, A.
Badel, B. Freminville, Y. Grattau, H. Bléhaut, Y. Herault, N. Janel, J.M. Delabar, DYRK1A, a
novel determinant of themethionine–homocysteine cycle in different mouse models
overexpressing this Down-syndrome-associated kinase, PLoS ONE 4 (2009) e7540.
[16] C. Noll, G. Lacraz, J. Ehses, J. Coulaud, D. Bailbe, J.L. Paul, B. Portha, F. Homo-Delarche,
N. Janel, Early reduction of circulating homocysteine levels in Goto-Kakizaki rat, a
spontaneous nonobese model of type 2 diabetes, Biochim. Biophys. Acta 1812
(2011) 699–702.
[17] F. Guedj, P.L. Pereira, S. Najas, M.J. Barallobre, C. Chabert, B. Souchet, C. Sebrie, C.
Verney, Y. Herault, M. Arbones, J.M. Delabar, DYRK1A: a master regulatory protein
controlling brain growth, Neurobiol. Dis. 46 (2012) 190–203.
[18] V. Fotaki, M. Dierssen, S. Alcantara, S. Martinez, E. Marti, C. Casas, J. Visa, E. Soriana,
X. Estivill, M.L. Arbones, Dyrk1A haploinsufﬁciency affects viability and causes de-
velopmental delay and abnormal brain morphology in mice, Mol. Cell. Biol. 22
(2002) 6636–6647.
[19] Y. Goto, M. Kakizaki, N. Masaki, Production of spontaneous diabetes by repetition of
selective breeding, Tohoku J. Exp. Med. 199 (1976) 85–90.
[20] B. Portha, G. Lacraz, M. Kergoat, F. Homo-Delarche, M.H. Giroix, D. Bailbé, M.N.
Gangnerau, M. Dolz, C. Tourrel-Cuzin, J. Movassat, The GK rat beta-cell: a prototype
for the diseased human beta-cell in type 2 diabetes? Mol. Cell. Endocrinol. 297
(2009) 73–85.
[21] L.J. Fortin, J. Genest, Measurement of homocyst(e)ine in the prediction of atheroscle-
rosis, Clin. Biochem. 28 (1995) 155–162.
[22] V. Ducros, K. Demuth, M.P. Sauvant, M. Quillard, E. Caussé, M. Candito, M.H. Read, J.
Drai, I. Garcia, M.F. Gerhardt, SFBC Working group on homocysteine. French Society
for Clinical Biology, Methods for homocysteine analysis and biological relevance of
the results, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 781 (2002) 207–226.
[23] C. Planque, J. Dairou, C. Noll, L.C. Bui, C. Ripoll, F. Guedj, J.M. Delabar, N. Janel, Mice
deﬁcient in cystathionine beta synthase display increased Dyrk1A and SAHH activ-
ities in brain, J. Mol. Neurosci. 50 (2013) 1–6.
[24] J.W. Miller, M.R. Nadeau, D. Smith, J. Selhub, Folate-deﬁciency induced
homocysteinaemia in rats: disruption of S-adenosylmethionine's co-ordinate regu-
lation of homocysteine metabolism, Biochem. J. 298 (1994) 415–419.
[25] A. Tlili, F. Jacobs, L. de Koning, S. Mohamed, L.C. Bui, J. Dairou, N. Belin, V. Ducros, T.
Dubois, J.L. Paul, J.M. Delabar, B. De Geest, N. Janel, Hepatocyte-speciﬁc Dyrk1a gene
transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in
hyperhomocysteinemic mice, Biochim. Biophys. Acta 1832 (2013) 718–728.
[26] N. Matsumoto, H. Ohashi, M. Tsukahara, K.C. Kim, E. Soeda, N. Niikawa, Possible
narrowed assignment of the loci of monosomy 21- associated microcephaly and in-
trauterine growth retardation to a 1.2-Mb segment at 21q22.2, Am. J. Hum. Genet.
60 (1997) 997–999.
[27] L.A. Harker, S.J. Slichter, C.R. Scott, R. Ross, Homocystinemia: vascular injury and ar-
terial thrombosis, N. Engl. J. Med. 291 (1974) 537–543.
[28] S. Schwarz, G.Z. Zhou, N-methyl-D-aspartate receptors and CNS symptoms of
homocystinuria, Lancet 337 (1991) 1226–1227.
[29] C.O. Harding, D.A. Pillers, R.D. Steiner, T. Bottiglieri, D.S. Rosenblatt, J. Debley, K.
Michael Gibson, Potential for misdiagnosis due to lack of metabolic derangement
in combinedmethylmalonic aciduria/hyperhomocysteinemia (cblC) in the neonate,
J. Perinatol. 23 (2003) 384–386.
[30] P. Mares, J. Folbergrova, H. Kubova, Excitatory amino acids and epileptic seizures in
immature brain, Physiol. Res. 53 (2004) S115–S124.
[31] A.F. Kamath, A.K. Chauhan, J. Kisucka, V.S. Dole, J. Loscalzo, D.E. Handy, D.D. Wagner,
Elevated levels of homocysteine compromise blood–brain barrier integrity in mice,
Blood 107 (2006) 591–593.
[32] B.S. Haggag, A.H. Hasanin,M.H. Raafat, H.S.A. Kawy, Lamotrigine decreased hippocam-
pal damage and improved vascular risk markers in a rat model of pentylenetetrazole
induced kindling seizure, Korean J. Physiol. Pharmacol. 18 (2014) 269–278.
[33] Y. Unlüçerçi, S. Bekpinar, F. Gürdöl, G. Seferoğlu, A study on the relationship be-
tween homocysteine and diabetic nephropathy in rats, Pharmacol. Res. 45 (2002)
249–252.
492 J.-M. Delabar et al. / Molecular Genetics and Metabolism Reports 1 (2014) 487–492[34] D. Lominadze, N. Tyagi, U. Sen, A. Ovechkin, S.C. Tyagi, Homocysteine alters cerebral
microvascular integrity and causes remodeling by antagonizing GABA-A receptor,
Mol. Cell. Biochem. 371 (2012) 89–96.
[35] B. Souchet, F. Guedj, I. Sahún, A. Duchon d, F. Daubigney, A. Badel, Y. Yanagawa, M.J.
Barallobre, M. Dierssen, E. Yu, Y. Herault, M. Arbones, N. Janel, N. Créau, J.M. Delabar,
Excitation/inhibition balance and learning are modiﬁed by Dyrk1a gene dosage,
Neurobiol. Dis. 69 (2014) 65–75.
[36] M. Pogribna, S. Melnyk, I. Pogribny, A. Chango, P. Yi, S.J. James, Homocysteinemetab-
olism in children with Down syndrome: in vitro modulation, Am. J. Hum. Genet. 69
(2001) 88–95.
[37] F. Licastro, A. Marocchi, S. Penco, E. Porcellini, D. Lio, G. Dogliotti, M.M. Corsi,
Does Down's syndrome support the homocysteine theory of atherogenesis?Experience in elderly subjects with trisomy 21, Arch. Gerontol. Geriatr. 43 (2006)
381–387.
[38] B. Chadefaux, M.O. Rethore, O. Raoul, I. Ceballos, M. Poissonnier, S. Gilgenkranz, D.
Allard, Cystathionine beta synthase: gene dosage effect in trisomy 21, Biochem.
Biophys. Res. Commun. 128 (1985) 40–44.
[39] R. De la Torre, S. De Sola, M. Pons, A. Duchon, M. Martınez de Lagran, M. Farre, M.
Fito, B. Benejam, K. Langohr, J. Rodriguez, M. Pujadas, J.C. Bizot, A. Cuenca, N. Janel,
S. Catuara, M.I. Covas, H. Blehaut, Y. Herault, J.M. Delabar, M. Dierssen, Epigallocate-
chin-3-gallate, a DYRK1A inhibitor, rescues cognitive deﬁcits in Down syndrome
mouse models and in humans, Mol. Nutr. Food Res. 58 (2014) 278–288.
